Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT02970669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Registry
-
NCT02970669
-
- Other papers using this trial's data
- The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02970669. Randomized; double masking; primary purpose other. Start 2016-12-16 (actual); primary completion 2018-03-19 (actual). Results posted on 2019-04-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
- Acronym
- AWAKE-HF
- Condition
- Heart Failure, Reduced Ejection Fraction
- Intervention (Drug)
- sacubitril/valsartan (LCZ696)
- Intervention (Drug)
- enalapril
- Intervention (Drug)
- matching placebo sacubitril/valsartan (LCZ696)
- Intervention (Drug)
- matching placebo enalapril
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02970669- Content hash
2b71eba5f84fcb4ab2afc85def1541b2f0294eb6f9533f63f2fd1760141500e3